James Heywood, MD
Advanced Heart Failure and Transplant Cardiology · la Jolla, CANPI 1285612457
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 18.3%. Reporting peaked in 2019 at $286,962 and has fallen 58.7% since, to $118,481 in 2025. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,762 payments — averaging $673.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$217K
- Actelion Pharmaceuticals US, Inc.$197K
- Abbott$153K
- Boehringer Ingelheim$142K
- Impedimed, Inc.$128K
- Novartis$76K
- plus $274K from 36 others
Across 131 payments — averaging $7339.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$439K
- Abbott$248K
- Janssen Research & Development, LLC$218K
- Medtronic$32K
- Endotronix, Inc.$22K
- Novartis$2K
What the payments were for
- Consulting fees$511,72043%
- Speaking & faculty fees$558,45847%
- Travel & lodging$79,0837%
- Food & beverage$36,6463%
- Education$5700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$178,398
- OPSUMIT$177,393
- JARDIANCE$174,617
- CLINICAL TRIAL PRODUCT$124,245
- CardioMEMS HF System$98,474
- ENTRESTO$74,331
- VERQUVO$43,293
- WINREVAIR$27,018
- Adempas$22,607
- TYVASO$19,242
- CARDIOMEMS$16,621
- HeartMate 3 Left Ventricular Dev$16,381
- Inpefa$14,894
- Solia$12,400
- Rivacor 7 DR-T$12,400
- Sentus$12,400
- Plexa ProMRI$12,400
- Acticor 7 VR-T DX$12,400
- OPTIMIZER$10,865
- Barostim Neo System$10,606
How this compares
$1,186,475 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 61 | $1,670,448 |
| OpsumitMacitentan | 33 | $395,226 |
| EntrestoSacubitril/Valsartan | 181 | $223,617 |
| AdempasRiociguat | 16 | $222,751 |
| JardianceEmpagliflozin | 112 | $144,027 |
| CamzyosMavacamten | 12 | $116,982 |
| EliquisApixaban | 72 | $92,709 |
| FarxigaDapagliflozin Propanediol | 47 | $56,409 |
| XareltoRivaroxaban | 25 | $28,095 |
| OzempicSemaglutide | 15 | $18,475 |
| Ambrisentan | 12 | $14,925 |
| Bumetanide | 31 | $3,011 |
| Eplerenone | 22 | $1,727 |
| Metoprolol Succinate | 107 | $1,568 |
| Spironolactone | 94 | $777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $3,733 | $1,763,157133 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $196,710 | $395,22633 claims |
| NovartisEntresto | $75,792 | $223,617181 claims |
| BayerAdempas | $26,508 | $222,75116 claims |
| Boehringer IngelheimJardiance | $141,612 | $144,027112 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $229 | $116,98212 claims |
| AstraZenecaFarxiga | $6,881 | $56,40947 claims |
| Johnson & JohnsonXarelto | $101 | $28,09525 claims |
| Novo NordiskOzempic | $2,802 | $18,47515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in la Jolla
- Rajeev Mohanla Jolla$357K
- Rola Khedrakila Jolla$82K
- Richard WrightSanta Monica$1.7M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
- Gurpreet SodhiSacramento$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.